Cerapedics

What Cerapedics does

Cerapedics is a privately-held commercial-stage medical device company headquartered in Westminster, Colorado, that develops and commercializes proprietary osteobiologic products for spinal fusion surgery. The company's core technology is the P-15 Osteogenic Cell Binding Peptide, a synthetic 15-amino-acid sequence derived from Type-1 collagen that is bound onto different osteoconductive scaffolds to accelerate bone formation through an attract-attach-activate mechanism. This technology is the basis for two FDA Premarket-Approved Class III drug-device combination products: i-FACTOR, approved in November 2015 for single-level anterior cervical discectomy and fusion (ACDF) and commercially launched in the U.S. in 2016, and PearlMatrix, approved in June 2025 for single-level transforaminal lumbar interbody fusion (TLIF) with expanded indications covering ALIF, PLIF, OLIF, and LLIF approved in January 2026. PearlMatrix is positioned as the first and only bone growth accelerator proven to accelerate lumbar fusion, backed by Level 1 clinical evidence from the ASPIRE IDE study (293 patients across 33 U.S. centers) and six-year i-FACTOR follow-up data showing 98.6% fusion rates.

Cerapedics generates revenue through direct hardware sales of bone graft products to hospitals and surgical centers, sold via a combination of direct sales representatives, local distribution partners, and group purchasing organization agreements with Premier Inc. and Vizient (the latter covering over 65% of U.S. acute care providers). International sales of i-FACTOR products are conducted through distributors, including Surgi-One in Canada, alongside CE Mark and TGA-listed products. The company serves spine surgeons and neurosurgeons performing cervical and lumbar fusion procedures, with named customers including Cleveland Clinic, Washington University School of Medicine, AdventHealth Avista, and Austin Brain and Spine. Pricing is not publicly disclosed, but products target the U.S. spinal bone graft substitution market, where approximately 465,000 fusion cases were performed in 2023.

The company employs approximately 250 people worldwide, has raised over $180 million cumulatively since 2007 across equity and debt rounds, and is led by Chairman and CEO Valeska Schroeder (appointed November 2022). KCK Group has been the lead institutional investor since a $22 million round in 2018, and the company is controlled by KCK Group as parent investor. The company has been recognized with industry awards including the 2018 MedTech Breakthrough Award for Best New Surgical Technology and Denver Post Top Workplaces in 2024 and 2026.

Name

Cerapedics

Legal name

Cerapedics Inc.

Website

https://cerapedics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Cerapedics is a Westminster, Colorado-based medical device company that develops and commercializes FDA PMA-approved P-15 peptide-enhanced bone graft products (i-FACTOR and PearlMatrix) for cervical and lumbar spinal fusion, sold to spine surgeons and hospitals through direct sales and GPO agreements with Premier Inc. and Vizient.

Ownership category

akta.pro rank

Product category

Spinal Bone Graft Substitutes / Orthobiologics

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industries

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB), Spine Implants & Motion Preservation (Fusion/Disc/Interspinous) (HLAHAEAC)

Keywords

• Bone graft substitutes
• Spinal fusion devices
• Osteobiologic products
• Peptide enhanced bone graft
• Spine surgery implants

Headquarters

HQ city

Westminster

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. i-FACTOR Bone Graft: FDA PMA-approved Class III drug-device combination product for single-level anterior cervical discectomy and fusion (ACDF). Commercialized since 2015/2016 in the U.S. market.
2. PearlMatrix Bone Graft: FDA PMA-approved Class III drug-device combination product for single-level transforaminal lumbar interbody fusion (TLIF). Approved June 2025 and now approved for expanded indications including ALIF, PLIF, OLIF, and LLIF approaches.
3. International Products: i-FACTOR products available internationally including i-FACTOR Putty and i-FACTOR Flex FR distributed through international markets. Products also available in Canada through distributor Surgi-One.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Cerapedics develops, manufactures, and commercializes novel osteobiologic bone graft products based on its proprietary P-15 Osteogenic Cell Binding Peptide technology. The company sells FDA PMA-approved Class III drug-device combination products, including i-FACTOR for cervical spine fusion (ACDF) and PearlMatrix for lumbar spine fusion (TLIF, ALIF, PLIF, OLIF, LLIF), targeting spine surgeons and healthcare facilities worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• PearlMatrix: P-15 Peptide Enhanced Bone Graft - FDA-approved Class III drug-device combination product for lumbar spine fusion (TLIF procedures). The first and only bone growth accelerator proven to accelerate lumbar fusion.
• i-FACTOR

Products and services

• i-FACTOR P-15 Peptide Enhanced Bone Graft FDA PMA-approved Class III drug-device combination bone graft using P-15 Osteogenic Cell Binding Peptide technology for single-level anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease. Has been used by surgeons since 2015/2016, with six-year IDE follow-up data showing 98.6% fusion rate. Targeted at spine surgeons seeking a clinically proven, cost-effective alternative to autograft for cervical fusion.
• PearlMatrix P-15 Peptide Enhanced Bone Graft FDA PMA-approved Class III drug-device combination bone graft using P-15 Osteogenic Cell Binding Peptide technology bound onto a flexible collagen matrix carrier. Indicated for single-level TLIF and now expanded for all major lumbar interbody surgical approaches (ALIF, PLIF, OLIF, LLIF). The first and only bone growth accelerator demonstrated to accelerate lumbar fusion in Level 1 IDE clinical data, with statistically superior time to fusion versus local autograft. Targeted at spine surgeons treating degenerative disc disease.
• i-FACTOR Flex FR Bone graft substitute utilizing P-15 Osteogenic Cell Binding Peptide technology with purified silk fibers as an inert carrier, providing enhanced cohesion, mechanical properties, and handling characteristics. Sterilized after packaging (terminally sterilized), stored at room temperature, with three-year shelf life, ready to use with no mixing or preparation. Distributed internationally.
• i-FACTOR Putty Bone graft substitute utilizing P-15 Osteogenic Cell Binding Peptide technology. Terminally sterilized after packaging, stored at room temperature, three-year shelf life, ready to use with no mixing or preparation required. Distributed internationally.
• i-FACTOR+ Matrix Next-generation P-15 Peptide Enhanced Bone Graft product approved by Health Canada, distributed in Canada through partner Surgi-One.

Quantifiable outcome

• More than twice as many patients fused at six months vs. local autograft in TLIF procedures
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• VizientcoreChannel Partner/ Reseller/ Distributor · 24 April 2026Cerapedics announced a supplier agreement with Vizient, the nation's largest provider-driven healthcare performance improvement company, to distribute PearlMatrix P-15 Peptide Enhanced Bone Graft. Vizient's clients include academic medical centers, community hospitals, and integrated health delivery networks serving over 65% of the nation's acute care providers.
• Surgi-OnecoreChannel Partner/ Reseller/ Distributor · 5 November 2020Surgi-One is the Canadian distributor for i-FACTOR products including i-FACTOR+ Matrix and other Cerapedics bone graft products in Canada.
• DSM MedicalminorStrategic or Co-development Partner · 25 October 2017Global life sciences company partnership mentioned in context of Cerapedics 'embarking on the next phase of commercializing novel osteobiologic products.'
• Premier Inc.coreChannel Partner/ Reseller/ Distributor · 30 November 2016Cerapedics was awarded a group purchasing agreement with Premier Inc. for Breakthrough Technology: Bone Tissue Synthetic Implantable Products. The agreement allows Premier members to access special pricing and terms pre-negotiated for i-FACTOR Peptide Enhanced Bone Graft. Premier unites approximately 3,750 U.S. hospitals and 130,000 other provider organizations.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global spine market leader with Infuse Bone Graft (rhBMP-2) and broader biologics portfolio including cellular bone matrices. Directly competes with Cerapedics in spine fusion bone grafts while serving as a broad incumbent across all spine surgery categories.
• Stryker: Major orthopedic and spine device manufacturer offering OP-1 (BMP-7) bone graft and broader orthobiologics portfolio. Competes with Cerapedics in spine fusion while also serving trauma, joint reconstruction, and other orthopedic segments.
• DePuy Synthes (Johnson & Johnson): Spine and orthobiologics division of J&J offering synthetic bone graft substitutes and demineralized bone matrix products. Competes with Cerapedics in cervical and lumbar fusion bone graft market through established hospital contracts.

Direct peers

• NuVasive: Spine-focused medical device company offering bone graft substitutes and orthobiologics alongside its spinal hardware portfolio. Direct competitor to Cerapedics in cervical and lumbar fusion bone graft market with similar target surgeon customers.
• Orthofix Medical: Spine and orthopedics company offering bone graft substitutes and biologics including Trinity ELITE and fiberFUSE Strip. Competes directly with Cerapedics in spine fusion orthobiologics with overlapping surgeon customer base.
• SeaSpine: Pure-play spine company offering OsteoStrand DBM, OsteoSurge DBM putty, and Accell bone matrix products. Direct competitor to Cerapedics in spine fusion biologics with similar commercial model targeting spine surgeons.
• Bioventus: Orthobiologics company offering bone graft substitutes including SIGNAFUSE and OSTEOAMP. Direct competitor to Cerapedics in spine and orthopedic bone graft markets with established commercial channels.
• Xtant Medical: Spine and orthopedic-focused orthobiologics company offering bone graft substitutes including OsteoVive Plus, 3Demin, and other DBM/synthetic products. Direct competitor to Cerapedics in spine fusion biologics market with comparable customer base.

Emerging players

• Isto Biologics: Orthobiologics company offering Influx bone graft substitute and other cell-based and synthetic bone graft products. Niche competitor in spine and orthopedic fusion markets with partial overlap with Cerapedics' P-15 technology approach.
• LifeNet Health: Non-profit tissue banking organization offering allograft bone graft products including VertiGraft and cellular bone matrices. Competes with Cerapedics in spine fusion through allograft-based alternatives, especially for surgeons preferring biological options.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CerapedicsInc
• LinkedInlinkedin.com/company/cerapedics

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerapedics